Aimovig™ (erenumab-aooe)

Aimovig is the first approved calcitonin-gene-related peptide (CGRP) blocker for the preventive treatment of migraine. Aimovig is manufactured by the partnership of Amgen and Novartis.1,2

What are the ingredients in Aimovig?

The active ingredient in Aimovig is erenumab-aooe, a monoclonal antibody.1

How does Aimovig work?

CGRP is a newly identified protein that acts like a neurotransmitter (a chemical messenger) throughout the brain and body. CGRP is found in large numbers in the trigeminal system, the sensory nerves that supply the head and neck, and research has shown that CGRP is found in high levels during a migraine attack.

Aimovig is a monoclonal antibody that targets and neutralizes the CGRP receptors. By not allowing CGRP to connect with its receptors, it is believed that Aimovig helps stop migraine attacks that were instigated by CGRP.1-3

What are the possible side effects of Aimovig?

The most common side effects experienced by patients receiving Aimovig in clinical trials were injection site reactions (pain, redness) and constipation.1

Things to know about Aimovig

The prefilled autoinjector contains natural rubber, which may cause allergic reactions in people who have a sensitivity to latex.1

Aimovig has not been studied in women who are pregnant or breastfeeding, and it is not known if Aimovig may cause any risks to unborn or breastfeeding infants.1

Aimovig has not been studied in children, and it is not known if Aimovig is safe to use in children with migraine.1

Dosing information

Aimovig is a self-administered injector given under the skin (subcutaneously) that is used once monthly to prevent migraine attacks in people who have chronic migraines. The recommended dosage is 70 mg once monthly, although some patients may benefit from a dosage of 140 mg once monthly, which is given as two consecutive 70 mg injections.1

For more information, read the full prescribing information of Aimovig.

View References